Starpharma to commence DEP cabazitaxel phase 1/2 trial
Filed with ASX · · 2 pages · English
Starpharma Holdings Limited on 6ix
Earlier from Starpharma
- VivaGel BV treatment clinical submission under rolling NDA
- NDA submission for VivaGel BV in the US
- VivaGel BV granted marketing approval in Australia
- Starpharma and Peter Mac Cancer Centre awarded DEP Grant
- AstraZeneca presents 1st DEP candidate as Bcl2/xL inhibitor
Later from Starpharma
- Starpharma receives $3.7M R&D tax incentive refund
- Starpharma completes US New Drug Application for VivaGel BV
- Appendix 4C - Quarterly Cashflow Report
- Mundipharma licenses Starpharmas VivaGel BV
- Starpharma licenses VivaGel BV to Mundipharma for Europe
Follow Starpharma into a list and get an email when it puts out news.
Follow Starpharma